IL142255A0 - Method of treating heparin-induced thrombocytopenia - Google Patents

Method of treating heparin-induced thrombocytopenia

Info

Publication number
IL142255A0
IL142255A0 IL14225599A IL14225599A IL142255A0 IL 142255 A0 IL142255 A0 IL 142255A0 IL 14225599 A IL14225599 A IL 14225599A IL 14225599 A IL14225599 A IL 14225599A IL 142255 A0 IL142255 A0 IL 142255A0
Authority
IL
Israel
Prior art keywords
induced thrombocytopenia
heparin
provides
treating heparin
treating
Prior art date
Application number
IL14225599A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL142255A0 publication Critical patent/IL142255A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL14225599A 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia IL142255A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10843298P 1998-11-13 1998-11-13
PCT/US1999/026770 WO2000029014A1 (en) 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia

Publications (1)

Publication Number Publication Date
IL142255A0 true IL142255A0 (en) 2002-03-10

Family

ID=22322154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14225599A IL142255A0 (en) 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia

Country Status (13)

Country Link
US (1) US6743426B2 (es)
EP (1) EP1128842B1 (es)
JP (1) JP2002529515A (es)
CN (1) CN1326355A (es)
AT (1) ATE320263T1 (es)
AU (1) AU1477000A (es)
BR (1) BR9915317A (es)
CA (1) CA2351067A1 (es)
DE (1) DE69930419T2 (es)
ES (1) ES2259248T3 (es)
IL (1) IL142255A0 (es)
WO (1) WO2000029014A1 (es)
ZA (1) ZA200102722B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
WO2008106584A1 (en) * 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
EP2170354A1 (en) * 2007-07-23 2010-04-07 University of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
WO1992011757A1 (en) 1991-01-11 1992-07-23 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA199900862A1 (ru) * 1997-03-24 2000-04-24 Эли Лилли Энд Компани Способ лечения сосудистых нарушений
WO1998048818A1 (en) * 1997-04-28 1998-11-05 Eli Lilly And Company Activated protein c formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP1128842B1 (en) 2006-03-15
DE69930419T2 (de) 2006-09-07
DE69930419D1 (de) 2006-05-11
AU1477000A (en) 2000-06-05
BR9915317A (pt) 2001-08-07
US20010018050A1 (en) 2001-08-30
ZA200102722B (en) 2002-05-03
ES2259248T3 (es) 2006-09-16
US6743426B2 (en) 2004-06-01
CN1326355A (zh) 2001-12-12
EP1128842A1 (en) 2001-09-05
ATE320263T1 (de) 2006-04-15
JP2002529515A (ja) 2002-09-10
WO2000029014A1 (en) 2000-05-25
CA2351067A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
DE69626660D1 (en) 2-alkylpyrrolidine
HK1008183A1 (en) Protein kinase c inhibitors.
GR3037074T3 (en) Protein kinase c inhibitors
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
AU7585598A (en) Raf kinase inhibitors
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
HK1057373A1 (en) Substituted triazole diamine derivatives as kinaseinhibitors
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
BG102259A (en) Compostions with controlled paroxetine release
AU5553296A (en) Arteriovenous and venous graft treatments: methods and compositions
IL142220A0 (en) Method of treating viral hemorrhagic fever
WO2000021513A3 (en) Methods for treating multiple sclerosis
MX9605072A (es) Dispositivo dispensador para pretratamiento.
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia
HU9700024D0 (en) Imidazopyridin-azolidinones
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
IL142249A0 (en) Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
CA2294243A1 (en) Novel cyanoaziridines for treating cancer
MX9603305A (es) Proceso mejorado para la ruptura de emulsiones de aceite.
EP0646651A3 (en) Method for improving the treatment of leather.
AU3145400A (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline